Descripción de negocio
Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. The R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.
Consejo de gestión & Consejo de supervisión
| CEO |
| Howard W. Robin |
| Consejo de gestión |
| Gil M. Labrucherie, Brian L. Kotzin, M.D., Dr. Dimitry S.A. Nuyten, Dr. Jonathan Zalevsky, Dr. Kevin Brodbeck, Dr. Urte Gayko, Jennifer Ruddock, Jilian B. Thomsen, John Northcott, Mark A. Wilson, Mary Tagliaferri, M.D., Robert Bacci |
| Consejo de supervisión |
| Robert B. Chess, Diana M. Brainard, Dr. Myriam J. Curet, Howard W. Robin, Jeff Ajer, Karin Eastham, R. Scott Greer, Roy A. Whitfield |
Datos de la empresa
| Nombre: |
Nektar Therapeutics Inc. |
| Dirección: |
455 Mission Bay Boulevard South,San Francisco, CA 94158, USA |
| Teléfono: |
+1-415-482-5300 |
| Fax: |
+1-415-339-5300 |
| E-mail: |
-
|
| Internet: |
https://www.nektar.com/ |
| Industria: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Subsector: |
Pharmaceuticals |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
- |
| Fecha de OPI: |
- |
Relación con inversores
| Nombre: |
Vivian Wu |
| IR teléfono: |
+1-628-895-0661 |
| IR-fax: |
- |
| IR e-mail: |
-
|
